


Schema



1. SOC biopsy and upper urinary tract mass on cross sectional imaging or directly visualized during upper tract endoscopy.
 2. Cisplatin-Eligible (CrCl > 50) will be randomized between Arms A and B; Cisplatin-Ineligible (CrCl >15 & ≤50, hearing loss grade ≥3, neuropathy grade ≥2, and/or ECOG PS=2) will be assigned to Arm C. See Section 3.2 for full eligibility criteria.
 3. aMVAC = accelerated methotrexate, vinblastine, doxorubicin and cisplatin with pegfilgrastim for 4 cycles; each cycle is 14 days.
 4. Durvalumab: 1500 mg IV every 28 days in Arm A, 1500 mg IV every 21 days in Arm C.
 5. Surgery = Radical nephroureterectomy and lymph node dissection (RNU).
 6. Follow up every 3-6 months for 5 years after surgery.